Tirzepatide for Masld
Verdict: Published with Warning
Across 4 PubMed studies, the evidence for Tirzepatide in Masld grades Tier B — preliminary evidence. Effective, but with safety or population caveats.
B 🟡 B Preliminary Evidence Published with Warning
Why this grade7-layer evidence engine
⚖️
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditableRaw score 0.61
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
B · Published with Warning
Confidence
82%
Highly consistent evidence
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)
▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.613
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高品質 SR/MA 顯示 positive (2 篇 > 0 negative)
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
PubMed studies (4)L2 · primary research & systematic reviews
Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis (SYNERGY-NASH)
Finding: MASH resolution without fibrosis worsening reached 44%/56%/62% in the tirzepatide 5/10/15 mg groups vs 10% placebo (P<0.001 for all three); the secondary fibrosis-improvement endpoint (>=1 stage) was 55%/51%/51% vs 30% placebo but was not multiplicity-adjusted and 95% CI lower bounds were only 5/1/1.
View on PubMed Efficacy of tirzepatide, lanifibranor, and resmetirom in MASLD: a meta-analysis of high-quality randomized controlled trials
Finding: Tirzepatide significantly reduced hepatic steatosis (MRI-PDFF MD -34.90%, 95% CI -53.31 to -16.49), ALT (-30.90%, P<0.00001) and AST (-20.71%, P<0.00001), with significant MASH resolution without worsening of fibrosis.
View on PubMed Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review and Meta-analysis
Finding: GLP-1-based therapies (incl. tirzepatide) reduced liver fat content (~5.21% absolute) and significantly improved ALT/AST/GGT, steatosis, ballooning and lobular inflammation, but fibrosis was only NON-significantly improved; authors state the evidence for tirzepatide was more robust than for semaglutide/liraglutide yet give no separate tirzepatide effect estimate.
View on PubMed Relationship Between Metabolic and Histological Responses in People With MASH With and Without T2D: SYNERGY-NASH Participant-Level Exploratory Analysis
Finding: MASH responders had greater weight loss (-16.0% vs -7.0%, P<0.001) and HbA1c reduction (-1.2% vs -0.6%, P<0.001) than non-responders, liver-fat normalization was a significant mediator, and histological benefit was consistent in patients with and without T2D.
View on PubMed Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …
L4a US FDA
Supportive
MOUNJARO is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. WARNING: RISK OF THYROID C-CELL TUMORS — Tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell … source↗
L4b EU EFSA
Supportive
Mounjaro received a marketing authorisation valid throughout the EU on 15 September 2022. The active substance in Mounjaro, tirzepatide, acts in the same way as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Mounjaro is a prescription-only medicine indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct… source↗
L4c UK NHS
Supportive
Tirzepatide is recommended as an option for managing overweight and obesity, alongside a reduced-calorie diet and increased physical activity in adults, only if they have: an initial body mass index (BMI) of at least 35 kg/m2 and at least 1 weight-related comorbidity. If less than 5% of the initial weight has been lost after 6 months on the highest tolerated dose, decide whether to continue tre… source↗
L4d TW TFDA / 衛福部
Supportive
猛健樂注射劑15毫克/0.5毫升 (MOUNJARO Injection 15mg/0.5mL)；許可證字號：衛部藥輸字第028468號；限由醫師使用；適應症：(1) 作為飲食及運動療法之外的輔助治療，用於改善第二型糖尿病成人病人之血糖控制；(2) 作為飲食及運動療法之外的輔助治療，用於體重控制（肥胖或過重）；申請商：台灣禮來股份有限公司；發證日期：112-07-19 source↗
L4e WHO
Supportive
Tirzepatide (GLP-1/GIP dual receptor agonist) used as glucose lowering therapy for adults with type 2 diabetes mellitus with established cardiovascular disease or chronic kidney disease and obesity. High prices of medicines like semaglutide and tirzepatide are limiting access to these medicines. source↗
L5a NIH Office of Dietary Supplements
Supportive
Tirzepatide functions as a dual agonist with greater affinity to GIP receptors than to GLP-1 receptors. FDA approvals: Type 2 Diabetes (Mounjaro) - May 2022 as adjunct to diet and exercise for glycemic control; Obesity (Zepbound) - November 2023 for chronic weight management in adults with obesity or overweight plus comorbidities; Obstructive Sleep Apnea (Zepbound) - December 2024 for moderate-… source↗
L5b Mayo Clinic
Neutral
Tirzepatide injection is used to treat type 2 diabetes, used together with diet and exercise to help control blood sugar. Tirzepatide injection is also used to help lose weight and keep the weight off in patients with obesity caused by certain conditions. It is also used to treat moderate to severe obstructive sleep apnea (OSA) in patients with obesity. source↗
L5c Cleveland Clinic
Supportive
These drugs reduce inflammation and fat in your liver. Examples are liraglutide (Victoza®, Saxenda®) semaglutide (Ozempic®, Wegovy®) and tirzepatide (Mounjaro®, Zepbound®). source↗
L5d Harvard Health
Supportive
Obesity drugs such as semaglutide (Wegovy) and tirzepatide (Zepbound) appear promising for reversing MASLD. source↗
L5e Specialty Society (condition-mapped)
Cautious
optimal management of comorbidities—including use of incretin-based therapies (e.g. semaglutide, tirzepatide) for type 2 diabetes or obesity source↗